nm23H1蛋白表达与卵巢癌腹膜后淋巴结转移及预后的关系  

Nucleoside diphosphate kinase/nm23H1 expression in ovarian epithelial carcinoma: retroperitoneal lymphatic metastasis and survival

作　　者：吴小华[1] 张志毅[1] 施达仁[1] 蔡树模[1] 陆洪芬[1] 范建玄[1] 

机构地区：[1]上海医科大学肿瘤医院妇科

出　　处：《中华医学杂志》1998年第4期275-277,共3页National Medical Journal of China

摘　　要：目的探讨核苷二磷酸激酶Ａ型［ＮＤＰＫ（Ａ）］在卵巢上皮癌中的表达及与腹膜后淋巴结转移和预后的关系。方法用免疫组织化学法测定ＮＤＰＫ（Ａ）在７４例卵巢癌原发灶、３１例腹腔和１８例腹膜后淋巴结转移灶中表达。结果在７４例原发灶中ＮＤＰＫ（Ａ）呈阳性表达２２例（３０％），阳性表达率在有腹膜后淋巴结转移者较无淋巴结转移者明显低（１７％比４６％，Ｐ＜０．０１）；在绝经前病例较绝经后病例高（４４％比１９％，Ｐ＝００２２）。与原发灶相比，在腹膜后淋巴结转移灶中表达率略低（２８％比３９％，Ｐ＞０．１）；而在腹腔转移灶中ＮＤＰＫ（Ａ）表达略高（３２％比１９％，Ｐ＞０５）。多因素分析表明，影响腹膜后淋巴结转移的危险因素是ＮＤＰＫ（Ａ）低表达、肿瘤分化较差和残留灶较大。但单、多因素分析均不能说明ＮＤＰＫ（Ａ）与生存率相关。结论上皮性卵巢癌中ＮＤＰＫ（Ａ）／ｎｍ２３Ｈ１的表达与腹膜后淋巴结转移呈负相关，而与预后关系不明显。Objective To determine the relationship between NDPK(A) expression and retroperitoneal lymph node metastasis (LNM) and the significance of the prognosis in epithelial ovarian carcinoma. Methods NDPK(A) expression of formalin fixed parafin beded samples, which included 74 primary, 31 intraperitoneal and 18 retroperitoneal lymph node metastatic tumors, were examined by ABC immunohistochemisty in 74 patients with primary ovarian cancer. Results In the 74 primary lesions, 22 samples showed positive staining of NDPK(A) (30%). Positive staining was higher in patients without LNM(46%) than those with LNM (17%, P =0 008); it was lower in menopausal patients (19%) than in menstruant (44%, P =0 022). Compared with primary tumor, NDPK(A) expression appeared to decrease in lymph node lesion(28% vs 39%, P >0 1) but to increase in intraperitoneal metastastic tumor (32% vs. 19%, P >0 5) Multivariance analysis confirmed that the important risk factors for LNM were lower expression of NDPK(A), more large residual tumor and poor differentiation. But there was no any corelation between NDPK(A) expression and survia. Conclusion The study suggested that increased expression of NDPK(A)/nm23H1 is inversely related to LNM in epithelial ovarian carcinoma, but it can not confirm the prognostic significance of NDPK(A).

关 键 词：卵巢肿瘤 肿瘤转移 淋巴结转移 预后 NM23H1 

分 类 号：R737.31[医药卫生—肿瘤] R733.4[医药卫生—临床医学]